News Release

Frequently Asked Questions Updated (2022-JAN-31)

Dear investors,

Please be advised that we have released in Tokyo Stock Exchange’s TDNet an official update to the F351 clinical trial press release of January 17th, 2022. In the update release, we have elaborated the roadmap from Phase III clinical trial to commercial launch. We have also updated the FAQ accordingly.

Thank you for your support and understanding.

Best regards,
Business Management / IR Team
GNI Group Ltd.